Clinical Trial Update: Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating rivaroxaban for efficacy and safety in supporting elective percutaneous coronary intervention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Coronary Artery Disease

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Cardiovascular Disease, Coronary Artery Disease | Phase 2 | Status: COMPLETED